Streetbeat News

Analyst Ratings

BTAI

BioXcel Therapeutics Inc's (NASDAQ:BTAI) stock has been downgraded from Buy to Hold by Truist due to significant near-term funding and clinical development challenges. The company's late-stage clinical programs and patent portfolio for Igalmi (dexmedetomidine) sublingual film are facing headwinds. The cash runway is a significant risk, and Truist would be more confident in BTAI if feedback from upcoming FDA meetings indicates a favorable clinical development path for Igalmi dementia and at-home use label extensions. BTAI shares are down 4.34% at $2.53.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 6:57 pm

PEGY

Northland Capital Markets has maintained an 'Outperform' rating on Pineapple Energy (NASDAQ:PEGY) but lowered the price target from $3.7 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:56 pm

FSLY

Raymond James analyst Frank Louthan has reiterated a Strong Buy rating on Fastly (NYSE:FSLY) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:54 pm

PBF

BMO Capital Markets analyst Phillip Jungwirth initiated coverage on PBF Energy Inc with an Outperform rating and a price target of $60. The analyst believes PBF has benefited the most during the refining upcycle, erasing elevated financial leverage seen during COVID. The company has developed from no assets to approximately 1 million barrels per day of processing capacity and has a negative net debt position. Jungwirth expects refining margins to remain above mid-cycle in 2024, supporting strong FCF generation and capital returns.

Portfolio Pulse from Lekha Gupta

October 05, 2023 | 6:51 pm

PTON

Evercore ISI Group analyst Shweta Khajuria maintains an In-Line rating on Peloton Interactive (NASDAQ:PTON) but lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:48 pm

CLX

Evercore ISI Group analyst Javier Escalante maintains an 'Underperform' rating on Clorox (NYSE:CLX) and has lowered the price target from $160 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:45 pm

ALPN

RBC Capital Markets has initiated coverage on Alpine Immune Sciences Inc (NASDAQ:ALPN) with an Outperform rating and a price target of $19. The analysts perceive ALPN's lead candidate, povetacicept, as having a robust foundation for advancement in autoimmune indications. The IgAN treatment market, the primary focus of the RUBY-3 trial, is estimated to be worth over $6 billion by 2032. ALPN shares are up 5.73% at $12.37.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 6:45 pm

CMBM

Roth MKM analyst Scott Searle maintains a 'Buy' rating on Cambium Networks (NASDAQ:CMBM) but has lowered the price target from $25 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:36 pm

MXCT

MaxCyte Inc (NASDAQ:MXCT) shares dropped after the company reported a 25-27% Y/Y decrease in preliminary Q3 revenue, attributed to reduced customer activity. The company also lowered its FY23 sales and core revenue forecasts. Analysts from William Blair noted that the company's underperformance in Processing Assembly sales had a cascading effect on Q3's Cell Therapy and Drug Discovery results. Despite the decline, lease revenue remained steady.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 6:35 pm

HELE

DA Davidson analyst Linda Bolton Weiser maintains a 'Buy' rating on Helen Of Troy (NASDAQ:HELE) but lowers the price target from $159 to $142.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:33 pm